NCT02275845

Brief Summary

Metformin vs Control to prevent gestational diabetes mellitus (GDM) in women with a high risk for GDM, an open label randomized controlled trial' The Medico-GDM trial

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Sep 2014

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2014

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

October 23, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 27, 2014

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2016

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2017

Completed
Last Updated

December 28, 2015

Status Verified

December 1, 2015

Enrollment Period

2 years

First QC Date

October 23, 2014

Last Update Submit

December 24, 2015

Conditions

Keywords

metforminprevention

Outcome Measures

Primary Outcomes (1)

  • incidence of gestational diabetes mellitus in both groups

    from 14 weeks pregnancy untill delivery

Secondary Outcomes (2)

  • Maternal outcomes

    from 14 weeks pregnancy untill delivery

  • Neonatal outcomes

    from 14 weeks pregnancy untill delivery

Study Arms (2)

intervention

EXPERIMENTAL

Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg. All the subjects are receiving a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.

Drug: MetforminOther: control diet

control diet

ACTIVE COMPARATOR

a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.

Other: control diet

Interventions

Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg (from 14 weeks pregnancy untill delivery)

intervention

2000 calories/day diet, with an adequate distribution of carbohydrates during the day

control dietintervention

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • a subject must meet all of the following criteria:
  • high risk (according to ductch national criteria) for gestational diabetes
  • aged between 18 and 40 years
  • gestational age between 8 and 12 weeks
  • and able to communicate and read in Dutch.

You may not qualify if:

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • no singleton pregnancy judged by ultrasonography
  • diagnosis of diabetes mellitus before the current pregnancy-
  • high fasting glucose at first trimester (\> 5.3 mmol/l)
  • cardiac insufficiency-\\
  • renal insufficiency (MDRD \< 60)
  • liver disease
  • use of medication other than Paracetamol or vitamins and incompetent women.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maasstad Ziekenhuis

Rotterdam, Netherlands

RECRUITING

MeSH Terms

Conditions

Diabetes, Gestational

Interventions

Metformin

Condition Hierarchy (Ancestors)

Pregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

BiguanidesGuanidinesAmidinesOrganic Chemicals

Study Officials

  • Joke van der Linden, dr.

    Maasstad Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
dr. J. van der Linden

Study Record Dates

First Submitted

October 23, 2014

First Posted

October 27, 2014

Study Start

September 1, 2014

Primary Completion

September 1, 2016

Study Completion

September 1, 2017

Last Updated

December 28, 2015

Record last verified: 2015-12

Locations